TY - JOUR
T1 - A randomized trial of aspirin to prevent colorectal adenomas
AU - Baron, John A.
AU - Cole, Bernard F.
AU - Sandler, Robert S.
AU - Haile, Robert W.
AU - Ahnen, Dennis
AU - Bresalier, Robert
AU - McKeown-Eyssen, Gail
AU - Summers, Robert W.
AU - Rothstein, Richard
AU - Burke, Carol A.
AU - Snover, Dale C.
AU - Church, Timothy R.
AU - Allen, John I.
AU - Beach, Michael
AU - Beck, Gerald J.
AU - Bond, John H.
AU - Byers, Tim
AU - Greenberg, E. Robert
AU - Mandel, Jack S.
AU - Marcon, Norman
AU - Mott, Leila A.
AU - Pearson, Loretta
AU - Saibil, Fred
AU - Van Stolk, Rosalind U.
PY - 2003/3/6
Y1 - 2003/3/6
N2 - BACKGROUND: Laboratory and epidemiologic data suggest that aspirin has an antineoplastic effect in the large bowel. METHODS: We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas. We randomly assigned 1121 patients with a recent history of histologically documented adenomas to receive placebo (372 patients), 81 mg of aspirin (377 patients), or 325 mg of aspirin (372 patients) daily. According to the protocol, follow-up colonoscopy was to be performed approximately three years after the qualifying endoscopy. We compared the groups with respect to the risk of one or more neoplasms (adenomas or colorectal cancer) at least one year after randomization using generalized linear models to compute risk ratios and 95 percent confidence intervals. RESULTS: Reported adherence to study medications and avoidance of nonsteroidal antiinflammatory drugs were excellent. Follow-up colonoscopy was performed at least one year after randomization in 1084 patients (97 percent). The incidence of one or more adenomas was 47 percent in the placebo group, 38 percent in the group given 81 mg of aspirin per day, and 45 percent in the group given 325 mg of aspirin per day (global P=0.04). Unadjusted relative risks of any adenoma (as compared with the placebo group) were 0.81 in the 81-mg group (95 percent confidence interval, 0.69 to 0.96) and 0.96 in the 325-mg group (95 percent confidence interval, 0.81 to 1.13). For advanced neoplasms (adenomas measuring at least 1 cm in diameter or with tubulovillous or villous features, severe dysplasia, or invasive cancer), the respective relative risks were 0.59 (95 percent confidence interval, 0.38 to 0.92) and 0.83 (95 percent confidence interval, 0.55 to 1.23). CONCLUSIONS: Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel.
AB - BACKGROUND: Laboratory and epidemiologic data suggest that aspirin has an antineoplastic effect in the large bowel. METHODS: We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas. We randomly assigned 1121 patients with a recent history of histologically documented adenomas to receive placebo (372 patients), 81 mg of aspirin (377 patients), or 325 mg of aspirin (372 patients) daily. According to the protocol, follow-up colonoscopy was to be performed approximately three years after the qualifying endoscopy. We compared the groups with respect to the risk of one or more neoplasms (adenomas or colorectal cancer) at least one year after randomization using generalized linear models to compute risk ratios and 95 percent confidence intervals. RESULTS: Reported adherence to study medications and avoidance of nonsteroidal antiinflammatory drugs were excellent. Follow-up colonoscopy was performed at least one year after randomization in 1084 patients (97 percent). The incidence of one or more adenomas was 47 percent in the placebo group, 38 percent in the group given 81 mg of aspirin per day, and 45 percent in the group given 325 mg of aspirin per day (global P=0.04). Unadjusted relative risks of any adenoma (as compared with the placebo group) were 0.81 in the 81-mg group (95 percent confidence interval, 0.69 to 0.96) and 0.96 in the 325-mg group (95 percent confidence interval, 0.81 to 1.13). For advanced neoplasms (adenomas measuring at least 1 cm in diameter or with tubulovillous or villous features, severe dysplasia, or invasive cancer), the respective relative risks were 0.59 (95 percent confidence interval, 0.38 to 0.92) and 0.83 (95 percent confidence interval, 0.55 to 1.23). CONCLUSIONS: Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel.
UR - http://www.scopus.com/inward/record.url?scp=0037421985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037421985&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa021735
DO - 10.1056/NEJMoa021735
M3 - Article
C2 - 12621133
AN - SCOPUS:0037421985
SN - 0028-4793
VL - 348
SP - 891
EP - 899
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 10
ER -